Clearmind Medicine Granted U.S. Patent for MEAI to Regulate Binge Behaviors
On June 18, 2026, Clearmind Medicine Inc. announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,350,242, titled 'BINGE BEHAVIOR REGULATORS.' The patent specifically covers innovative compositions and methods utilizing a pharmaceutically acceptable salt of the company's molecule MEAI (5-methoxy-2-aminoindane) to regulate binge behaviors. These behaviors include excessive drinking, eating, and gambling. This new patent increases Clearmindβs global intellectual property portfolio to 32 granted patents across 19 patent families. CEO Dr. Adi Zuloff-Shani stated that this milestone directly supports the company's clinical programs for binge-related disorders, most notably alcohol use disorder (AUD), which is the focus of their lead candidate, CMND-100. Clearmind is a clinical-stage biotech focused on developing non-hallucinogenic, second-generation neuroplastogens to treat major under-served health problems. The company continues to seek broad IP protection for its CNS therapeutic technologies in major global markets.